

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”, together with the Circular, the “**AGM Documents**”) of the annual general meeting (the “**2025 AGM**”) of Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 (the “**Company**”) both dated April 28, 2026. Unless otherwise specified, capitalized terms used herein shall have the same meaning as those defined in the AGM Documents.

ATTENDANCE AT THE 2025 AGM

The Board is pleased to announce that the 2025 AGM was convened and held at 2:00 p.m. on Thursday, May 28, 2026 at Meeting Room, 3/F, Block 5, B Area, No. 777 Binhai 4th Road, Hangzhou Bay New Area, Ningbo, Zhejiang Province, PRC.

The 2025 AGM was convened by the Board in accordance with the Company Law of the PRC (《中華人民共和國公司法》), the Listing Rules and the Articles of Association, and chaired by Mr. Pan Fei, the executive Director and the chief executive officer. All Directors attended the 2025 AGM either in person or by electronic means.

As at the date of the 2025 AGM, the total number of issued Shares (excluding treasury shares, if any) was 417,167,290 Shares, comprising 310,306,209 H Shares and 106,861,081 Unlisted Shares. The total number of Shares entitling the Shareholders to attend and vote for or against or abstain from voting on the proposed resolutions at the 2025 AGM was 417,167,290. Shareholders holding a total of 299,089,495 Shares and representing approximately 71.70% of the total number of issued Shares (excluding treasury shares, if any) (including their proxies and authorized representatives) attended the 2025 AGM. The proposed resolutions as set out in the Notice were voted by way of poll at the 2025 AGM.

Pursuant to a concert party agreement dated March 16, 2021, Mr. LV Shiwen and Ms. LI Hui have been acting in concert in the management and operation of the Company, its subsidiaries, and any predecessors of the same. As of the date of this announcement, Mr. LV Shiwen, the chairman of the Board of the Company, controls the general partner of each of Ningbo Sangdi Investment Management L.P. (Limited Partnership) (寧波桑迪投資管理合夥企業(有限合夥)), Ningbo Mukang Venture Capital Partnership (Limited Partnership) (寧波沐康創業投資合夥企業(有限合夥)), Ningbo Kefeng Investment Management L.P. (Limited Partnership) (寧波鈞豐投資管理合夥企業(有限合夥)) and Hainan Maidi Enterprise Management L.P. (Limited Partnership) (海南脈迪企業管理合夥企業(有限合夥)), namely, Ningbo Dixiang Venture Capital Co., Ltd. (寧波迪翔創業投資有限公司). Ningbo Linfeng Biotechnology Co., Ltd. (寧波麟豐生物科技有限公司) is owned as to 65% by Shanghai Shidi Industrial Development Co., Ltd. (上海仕地實業發展有限公司), which in turn is wholly-owned by Ms. LI Hui. As a result of the above, each of Mr. LV Shiwen, Ms. LI Hui, Ningbo Sangdi Investment Management L.P. (Limited Partnership), Ningbo Mukang Venture Capital Partnership (Limited Partnership), Ningbo Kefeng Investment Management L.P. (Limited Partnership), Hainan Maidi Enterprise Management L.P. (Limited Partnership), Shanghai Shidi Industrial Development Co., Ltd., Ningbo Linfeng Biotechnology Co., Ltd. and Ms. DU Jiliu, representing an aggregate of 114,102,471 Shares was required to abstain and had abstained from voting on the sixth resolution proposed at the AGM concerning the remuneration of the Directors.

The holder under the H Share Scheme holding 354,000 H Shares as at the opening of business on the date of the 2025 AGM was required to abstain and had abstained from voting on the proposed resolutions at the 2025 AGM pursuant to Rule 17.05A of the Listing Rules.

As at the date of the 2025 AGM, there were no treasury shares held by the Company (including treasury shares held or deposited with CCASS) and as such, no holders of treasury shares were required to abstain from voting at the 2025 AGM, and no repurchased Shares and therefore no Shares are pending cancellation which should be excluded from the total number of issued Shares entitled to attend and vote on the proposed resolutions at the 2025 AGM.

Save as disclosed herein, to the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the 2025 AGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the 2025 AGM; and (3) no party has stated any intention in the Circular to vote against or abstain from voting on the resolutions proposed at the 2025 AGM.

POLL RESULTS OF THE 2025 AGM

The poll results of the resolutions proposed at the 2025 AGM were as follows:

Ordinary Resolutions		Number of votes (%)			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the resolution on the report of the board of directors of the Company for the year 2025.	299,089,495 (100.000000%)	0 (0.000000%)	0 (0.000000%)	Yes
2.	To consider and approve the resolution on the audited consolidated financial statements of the Group for the year 2025.	299,089,495 (100.000000%)	0 (0.000000%)	0 (0.000000%)	Yes
3.	To consider and approve the resolution on the annual report of the Group for the year 2025.	299,089,495 (100.000000%)	0 (0.000000%)	0 (0.000000%)	Yes
4.	To consider and approve the resolution on the profit distribution plan of the Company for the year 2025.	299,089,495 (100.000000%)	0 (0.000000%)	0 (0.000000%)	Yes
5.	To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for 2026, for a term commencing from the date of approval at the 2025 AGM until the conclusion of the 2026 annual general meeting of the Company, and authorise the board of directors of the Company to determine the specific matters, including but not limited to their remunerations, in relation to such re-appointment.	299,089,495 (100.000000%)	0 (0.000000%)	0 (0.000000%)	Yes
Ordinary Resolutions		Number of votes (%)			Passed by Shareholders
		For	Against	Abstain	
6.	To determine the remuneration of the directors of the Company.	219,924,136 (100.000000%)	0 (0.000000%)	0 (0.000000%)	Yes
Special Resolutions					
7.	Proposed granting of general mandate to issue shares.	298,940,895 (99.950316%)	148,600 (0.049684%)	0 (0.000000%)	Yes
8.	Proposed granting of general mandate to repurchase H shares.	299,089,495 (100.000000%)	0 (0.000000%)	0 (0.000000%)	Yes

For details of each of the above resolutions proposed at the 2025 AGM, please refer to the Circular.

As more than half of the votes were cast in favor of the ordinary resolutions numbered 1 to 6 above, and as more than two-thirds of the votes were cast in favor of the special resolutions numbered 7 to 8 above, all resolutions proposed at the 2025 AGM were duly passed by way of poll by the Shareholders as ordinary resolutions and special resolutions of the Company.

SCRUTINEERS

The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the 2025 AGM. Two representatives of the Shareholders and one lawyer of Commerce & Finance Law Offices participated in the scrutiny of the poll results at the 2025 AGM.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei

Executive Director and Chief Executive Officer

Hong Kong, May 28, 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.